Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy
Author:
Ziegler Dan1, Ametov Alexander2, Barinov Alexey3, Dyck Peter J.4, Gurieva Irina5, Low Phillip A.4, Munzel Ullrich6, Yakhno Nikolai3, Raz Itamar7, Novosadova Maria5, Maus Joachim6, Samigullin Rustem6
Affiliation:
1. German Diabetes Clinic, German Diabetes Center, Leibniz Institute at the Heinrich Heine University, Düsseldorf, Germany 2. Russian Medical Academy for Advanced Studies, Moscow, Russia 3. Neurology Clinic, Moscow Medical Academy, Moscow, Russia 4. Department of Neurology, Mayo Clinic, Rochester, Minnesota 5. Federal Center for Diabetic Foot, Moscow, Russia 6. MEDA Pharma, Bad Homburg, Germany 7. Hadassah University, Jerusalem, Israel
Abstract
OBJECTIVE—The aim of this trial was to evaluate the effects of α-lipoic acid (ALA) on positive sensory symptoms and neuropathic deficits in diabetic patients with distal symmetric polyneuropathy (DSP).
RESEARCH DESIGN AND METHODS—In this multicenter, randomized, double-blind, placebo-controlled trial, 181 diabetic patients in Russia and Israel received once-daily oral doses of 600 mg (n = 45) (ALA600), 1,200 mg (n = 47) (ALA1200), and 1,800 mg (ALA1800) of ALA (n = 46) or placebo (n = 43) for 5 weeks after a 1-week placebo run-in period. The primary outcome measure was the change from baseline of the Total Symptom Score (TSS), including stabbing pain, burning pain, paresthesia, and asleep numbness of the feet. Secondary end points included individual symptoms of TSS, Neuropathy Symptoms and Change (NSC) score, Neuropathy Impairment Score (NIS), and patients’ global assessment of efficacy.
RESULTS—Mean TSS did not differ significantly at baseline among the treatment groups and on average decreased by 4.9 points (51%) in ALA600, 4.5 (48%) in ALA1200, and 4.7 (52%) in ALA1800 compared with 2.9 points (32%) in the placebo group (all P < 0.05 vs. placebo). The corresponding response rates (≥50% reduction in TSS) were 62, 50, 56, and 26%, respectively. Significant improvements favoring all three ALA groups were also noted for stabbing and burning pain, the NSC score, and the patients’ global assessment of efficacy. The NIS was numerically reduced. Safety analysis showed a dose-dependent increase in nausea, vomiting, and vertigo.
CONCLUSIONS—Oral treatment with ALA for 5 weeks improved neuropathic symptoms and deficits in patients with DSP. An oral dose of 600 mg once daily appears to provide the optimum risk-to-benefit ratio.
Publisher
American Diabetes Association
Subject
Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference33 articles.
1. Shaw JE, Zimmet PZ, Gries FA, Ziegler D: Epidemiology of diabetic neuropathy. In Textbook of Diabetic Neuropathy. Gries FA, Cameron NE, Low PA, Ziegler D, Eds. New York, Thieme, 2003, p. 64–82 2. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care 27: 1458–1486, 2004 3. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956–962, 2005 4. Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH: Showing neuropathy is related to increased mortality in diabetic patients: a survival analysis using an accelerated failure time model. J Clin Epidemiol 53:519–523, 2000 5. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ: Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 21:976–982, 2004
Cited by
447 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|